Retatrutide
Retatrutide
Retatrutide (LY‑3437943) is sold strictly as a research peptide. A tri‑agonist that activates GLP‑1, GIP, and glucagon receptors, making it a cutting‑edge compound for metabolic research.
What Retatrutide Is Claimed to Do
Mechanism
Targets three metabolic receptors simultaneously:
-
GLP‑1: appetite reduction, insulin secretion
-
GIP: insulin sensitivity
-
Glucagon: increased energy expenditure
This triple action is described as more potent than semaglutide or tirzepatide.
Research Applications
-
Weight‑loss studies
-
Diabetes and glucose control
-
Metabolic syndrome
-
Fatty liver disease
-
Dyslipidaemia
Reported Clinical Findings
-
Up to 24% weight reduction in 48 weeks (Phase 2 data)
-
Better results than semaglutide (17.4% in 68 weeks)
-
Better results than tirzepatide (20.9% in 72 weeks)
-
GI side effects common; lower starting doses reduce them
Safety & Compliance Notes
-
For researchers aged 18+
-
Must be stored at 2–8°C, not frozen
-
Potential risks (based on similar drugs):
-
Pancreatitis
-
Gallbladder issues
-
Not suitable for those with MTC or MEN2 history
-
Administration
-
Once‑weekly subcutaneous injection
-
Typical titration: 2 mg → 4 mg → 8 mg → 12 mg
-
Rotate injection sites, maintain sterility
FAQ Highlights
-
Legal in the UK for research use
-
Not a prescription medicine
-
May slow gastric emptying (affects absorption of other drugs)
-
Slight lean‑mass preservation but not a muscle‑building peptide